Chinanews Client Beijing, November 26 (Reporter Zhang Ni) The reporter learned from the National Medical Insurance Administration that on November 26, the insulin-specialized country organized the centralized procurement of drugs in Shanghai to open the bid, resulting in the proposed selection.
This collection covers the second- and third-generation insulins commonly used in clinical practice, including 16 varieties with generic names.
The purchase demand of medical institutions nationwide in the first year is about 210 million. Based on the pre-collection price, the purchase amount involved is about 17 billion yuan.
Data map: People line up for registration in the outpatient building of a hospital.
Photo by China News Agency reporter Yin Liqin
According to reports, pharmaceutical companies actively participated in this centralized procurement, and 11 companies participated in the bidding.
The average price of the products to be selected is reduced by 48%, which is expected to save 9 billion yuan each year.
All domestic and foreign companies in this centralized procurement have their products selected. The products to be selected include products from well-known companies commonly used by medical institutions and products from emerging companies. While reducing the falsely high prices, they have achieved a higher match with actual clinical needs. Spend.
Taking the commonly used insulin glargine as an example, from an average of 180 yuan per tube to about 70 yuan per tube, each patient can save about 4,000 yuan per year.
This centralized procurement adhered to the "integration of recruitment and procurement, linked to volume and price", and on the basis of the successful experience in the early exploration of centralized procurement of drugs and consumables, the procurement rules were optimized for the characteristics of insulin.
One is to fully respect clinical choices, maintain the stability of clinical medications, and reduce the risk of substitution.
The second is the combined competition of different generic names of insulin with the same therapeutic purpose and clinical mechanism of action, taking into account the needs of clinical use and the sufficiency of competition.
The third is to attach great importance to the supply of selected products. According to the characteristics of insulin production and use, we will take multiple measures to ensure the supply through the bottom-line survey of production capacity and sufficient production preparation time.
Insulin is an important drug for diabetic patients to control blood sugar and has an irreplaceable position in the treatment of diabetes.
Because insulin needs to be used for a long time, the falsely high price brings a heavy burden to patients.
This special insulin procurement is the first time that the state organizes centralized drug procurement to expand into the field of biological drugs. It is an important milestone in the process of centralized procurement reform. It not only promotes the return of insulin prices to a reasonable level and benefits more patients, but also contributes to the improvement of the centralized procurement system and the realization of reforms. Goals are also important.
(over)